Novo Nordisk bulks up in rare diseases with $1.2bn Prothena deal
pharmaphorum
JULY 13, 2021
Diabetes giant Novo Nordisk has opened a new front in its rare disease R&D, thanks to an acquisition agreement with Prothena focusing on drugs for ATTR amyloidosis. In ATTR amyloidosis, transthyretin (TTR) protein misfolds and accumulates as amyloid deposits throughout the body. billion by 2025.
Let's personalize your content